Lipid Compositions for Glaucoma IOP Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for glaucoma, particularly those targeting the conventional aqueous outflow pathway, are limited in effectiveness and often accompanied by significant side effects, with no known drugs efficiently increasing intraocular pressure (IOP) through this pathway except for prostaglandins, which primarily utilize the uveoscleral pathway.
Innovation Solution
Development of compositions containing specific naturally occurring or synthesized lipids, such as phosphatidylserines, phosphatidylcholines, and sphingomyelin, that are endogenous to non-glaucomatous aqueous humor but depleted in glaucomatous conditions, which are administered topically to promote aqueous outflow through the trabecular meshwork, thereby reducing IOP.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If prostaglandin analogs are used to treat glaucoma, then aqueous outflow is increased and IOP is reduced, but the conventional outflow pathway is not effectively targeted and significant side effects occur
Solution Approach 1:
The patent changes the chemical parameter from prostaglandin analogs to specific lipids (phosphatidylserine, phosphatidylcholine, sphingomyelin, psychosine) that are endogenous to non-glaucomatous aqueous humor. This parameter change targets the conventional outflow pathway specifically, achieving IOP reduction with potentially fewer side effects since these lipids are naturally occurring in healthy eyes.
Solution Approach 2:
The patent utilizes lipids that are naturally present in non-glaucomatous aqueous humor (phosphatidylserine, phosphatidylcholine, sphingomyelin, psychosine), allowing the body's own biochemical environment to facilitate treatment. This self-service approach may reduce immunogenicity and side effects compared to exogenous prostaglandin analogs.
2Adaptability or versatility
If new therapeutics targeting the conventional pathway are developed, then aqueous outflow through TM is promoted and IOP is reduced, but the lack of existing drugs for this pathway represents a therapeutic gap
Solution Approach 1:
The patent segments the aqueous outflow pathway into conventional (TM) and uveoscleral pathways, and specifically targets the conventional pathway with lipid compositions. This segmentation allows for pathway-specific treatment, addressing the therapeutic gap by providing drugs that act on the conventional pathway rather than relying on uveoscleral pathway activation.
Solution Approach 2:
The patent introduces lipids (phosphatidylserine, phosphatidylcholine, sphingomyelin, psychosine) as intermediary substances that mediate between the administered composition and the trabecular meshwork cells. These lipids serve as biochemical messengers that restore normal lipid levels in the aqueous humor, thereby promoting conventional outflow without requiring direct stimulation of alternative pathways.
3Reliability
If lipid compositions are administered topically, then aqueous outflow through trabecular meshwork is enhanced and IOP is lowered, but the identification and quantification of endogenous lipids presents analytical challenges
Solution Approach 1:
The patent replaces traditional mechanical chromatographic and NMR techniques with mass spectrometry for lipid identification and quantification. This substitution overcomes the limitations of requiring large sample amounts and complex chemistry, enabling sensitive detection of endogenous lipids at low concentrations in aqueous humor.
Solution Approach 2:
The patent employs mass spectrometry which detects lipids based on their mass-to-charge ratio, creating a spectral fingerprint for each lipid species. This analytical approach allows for precise identification and quantification of phosphatidylserine, phosphatidylcholine, sphingomyelin, and psychosine without requiring large amounts of purified material.
Data Source
Figure 1A~1B
Figure 2A~2B
Figure 3
AI summary
Compositions, kits, and methods for reducing intraocular pressure (IOP) in a subject (e.g., human) include at least one naturally occurring or synthesized version or analog thereof of a lipid (e.g., a phosphoserine, a phosphocholine, a psychosine or other glycolipid) that is endogenous to non-glaucomatous aqueous humor in a subject and that lowers IOP in the subject, in a therapeutically effective amount for promoting aqueous outflow through TM in at least one eye of the subject and reducing IOP in the subject. The compositions can be used for, e.g., treating glaucomas, including, for example, primary open angle glaucoma (POAG) and normal tension glaucoma (NTG).